As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
REGULATORY
Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
Komeito submitted a petition to the Japanese government on February 28 asking them to introduce market incentives for and support the domestic production of nacubactam, an antibacterial for antimicrobial-resistant bacteria being developed by Meiji Seika Pharma. The petition was submitted…
To read the full story
Related Article
- Global PIII Launched for Novel β-Lactamase Inhibitor Nacubactam: Meiji
April 27, 2023
- Japan to Lead Discussions on AMR Measures at G7 Summit: PM
March 7, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
REGULATORY
- LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
- Label Updated for Gazyva and Imbruvica: PMDA
November 25, 2025
- Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- Japan to Launch Panel Next Year to Discuss Third-Party Access to Vaccination Database
November 25, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…